Familial hypercholesterolemia and lipoprotein(a) hyperlipidemia as independent and combined cardiovascular risk factors

Atherosclerosis Supplements

Volumn 10, Issue 5, 2009, Pages 74-78

  Orsó, Evelyn ^a   Ahrens, Norbert ^a   ć, Dzenan ^a   Schmitz, Gerd ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Biomarker; Cardiovascular risk; Familial hypercholesterolemia; Lipoprotein apheresis; Lipoprotein(a) hyperlipidemia

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTILIPEMIC AGENT; APOLIPOPROTEIN A; APOLIPOPROTEIN B; BIOLOGICAL MARKER; CD36 ANTIGEN; DEFENSIN; DEFENSIN 1; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; NICOTINIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 2; SCAVENGER RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; UNCLASSIFIED DRUG;

APHERESIS; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIARRHEA; DISEASE SEVERITY; FAMILIAL HYPERCHOLESTEROLEMIA; FLUSHING; HEART RATE; HUMAN; HYPERLIPIDEMIA; KRINGLE DOMAIN; LIPOPROTEIN A HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK ASSESSMENT; SIDE EFFECT; VOMITING;

BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; LIPOPROTEIN(A); PHENOTYPE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 72649101507     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(09)71816-1     Document Type: Article

References (28)

1. Daniels S.R., Greer F.R., and the Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 122 (2008) 198-208
2. Berenson G.S., Srinivasan S.R., Bao W., Newman III W.P., Tracy R.E., and Wattigney W.A. Association between multiple cardiovascular risk factors and the early development of atherosclerosis. Bogalusa Heart Study. N Engl J Med 338 (1998) 1650-1656
3. Bhatnagar D. Diagnosis and screening for familial hyper cholesterolemia: finding the patient, finding the genes. Ann Clin Biochem 43 (2006) 441-456
4. Lambert G., Charlton F., Rye K.A., and Piper D.E. Molecular basis of PCSK9 function. Atherosclerosis 203 (2009) 1-7
5. Stolt P.C., and Bock H.H. Modulation of lipoprotein receptor functions by intracellular adaptor proteins. Cell Signal 18 (2006) 1560-1571
6. National Institute for Health and Clinical Excellence. Identification and management of familial hypercholesterolemia. NICE clinical guideline 71; August 2008.
7. Thompson G.R., Barbir M., Davies D., et al. Recommendations for the use of LDL apheresis. Atherosclerosis 198 (2008) 247-255
8. Thompson GR, Barbir M, Davies D, et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2009; in press.
9. Berg K. A new serum type system in man - the Lp system. Acta Pathol Microbiol Scand 59 (1963) 369-382
10. Utermann G. The mysteries of lipoprotein(a). Science (Washington, DC) 246 (1998) 904-910
11. Leischik R., and Dworrak B. Lipoprotein(a): Bedeutung für das fibrinolytische System und thromboembolische Komplikationen. Herz 31 (2006) 144-152
12. Rubin J., Kim H.J., Pearson T.A., et al. The apolipoprotein(a) gene: linkage disequilibria at three loci differs in African Americans and Caucasians. Atherosclerosis 201 (2008) 138-147
13. Chretien J.P., Coresh J., Berthier-Schaad Y., et al. Three single- nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African Americans compared with European Americans. J Med Genet 43 (2006) 917-923
14. Rasouli M., and Kiasari A.M. Interactions of lipoprotein(a) with diabetes mellitus, apolipoprotein B and cholesterol enhance the prognostic values for coronary artery disease. Clin Chem Lab Med 46 (2008) 667-673
15. Caplice N.M., Panetta C., Peterson T.E., et al. Lipoprotein(a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 98 (2001) 2980-2987
16. D'Angelo A., Geroldi D., Hancock M.A., et al. The apolipoprotein(a) component of lipoprotein(a) mediates binding to laminin: contribution to selective retention of lipoprotein(a) in atherosclerotic lesions. BBA 1687 (2005) 1-10
17. Tsimikas S., and Witztum J.L. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol 19 (2008) 369-377
18. Blencowe C., Hermetter A., Kostner G.M., et al. Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein(a) in comparison with low density lipoprotein. J Biol Chem 270 (1995) 31151-31157
19. Hoover-Plow J., Hart E., Gong Y., Shchurin A., and Schneeman T. A physiological function for apolipoprotein(a): a natural regulator of the inflammatory response. Exp Biol Med 234 (2009) 28-34
20. Jaeger B.R., Richter Y., Nagel D., et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 6 (2009) 229-239
21. Kraft H.G., Lingenhel A., Raal F.J., Hohenegger M., and Utermann G. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 20 (2000) 522-528
22. Delport R., Lingenhel A.W., Ubbink J.B., and Kraft H.G. Hyperhomocyst(e) inemia is an important risk factor for vascular diseasein subjects with high-molecular weight apo(a) isoforms. Cardiovasc J South Afr 15 (2004) 207-213
23. Anuurad E., Rubin J., Chiem A., et al. High levels of inflammatory biomarkers are associated with increased allele-specific apolipoprotein(a) levels in African-Americans. J Clin Endocrinol Metab 93 (2008) 1482-1488
24. Mosig S., Rennert K., Buettner P., et al. Monocytes of patients with familial hypercholesterolemia show alterations in cholesterol metabolism. BMC Med Genom 1 (2008) 60-71
25. Buechler C., Ullrich H., Ritter M., et al. Lipoprotein(a) up-regulates the expression of the plasminogen activator inhibitor 2 in human monocytes. Blood 97 (2001) 981-986
26. Buechler C., Ullrich H., Aslanidis C., et al. Lipoprotein(a) down-regulates lisosomal acid lipase and induces interleukin-6 in human blood monocytes. BBA 1642 (2003) 25-31
27. Lobov S., Croucher D.R., Saunders D.N., and Ranson M. Plasminogen activator inhibitor type 2 inhibits cell surface associated tissue plasminogen activator in vitro. Thromb Haemost 100 (2008) 319-329
28. Tselmin S., Schmitz G., Julius U., Bornstein S.R., and Graessler J. Acute effects of lipid apheresis on human serum lipidome. Atherosclerosis 10 (2009) 27-33